Inhibitory effect of dilazep hydrochloride on the formation of advanced glycation end products

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 4, 2000, Pages 191-198

  Tanaka, Yasushi ^a   Inoue, Keisuke ^b   Shimada, Satoshi ^a   Shimizu, Tomoaki ^a   Kawasumi, Masahiko ^a   Iwamoto, Hisahiko ^c   Onuma, Tomio ^a   Kawamori, Ryuzo ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b KOWA COMPANY LTD   (Japan)

^c Kashima Works   (Japan)

Author keywords

Advanced glycation end products; Aminoguanidine; Diabetes; Dilazep hydrochloride

Indexed keywords

2,3 DIHYDROXYBENZOIC ACID; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; DILAZEP; DIMETHYL SULFOXIDE; FREE RADICAL; GENTISIC ACID; HYDROXYL RADICAL; SCAVENGER;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DRUG MECHANISM; DRUG POTENCY; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 0034023709     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)89033-5     Document Type: Article

References (20)

1. 1. Bahn HF, Higgins PJ. Reaction of monosaccharides with proteins: Possible evolutionary significance. Science. 1981;213:222-224.
2. 2. Monnier VM. Nonenzymatic glycosylation, the Maillard reaction and the aging process. J Gerontol. 1990;45:B105-B111.
3. 3. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. New Engl J Med. 1988;318:1315-1321.
4. 4. Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of "autoxidative glycosylation" in diabetes. Biochem J. 1987;245:243-250.
5. 5. Hunt JV, Dean RT, Wolff SP, et al. Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Biochem J. 1993; 291:529-535.
6. 6. Cheeseman KH, Forni LG. An investigation of the novel anti-inflammatory agents ONO-3144 and MK-447. Studies on their potential antioxidant activity. Biochem Pharmacol. 1988;37:4225-4233.
7. 7. Takagi Y, Kashiwagi A, Tanaka Y, et al. Significance of fructose-induced protein oxidation and formation of advanced glycation end product. J Diabetes Complications. 1995; 9:87-91.
8. 8. Takenaga M, Kitagawa H, Hirai A, et al. Mechanism of anti-platelet aggregating action of dilazep. J Pharmacobiodyn. 1985;8:77-83.
9. 9. Yoshinaka Y, Yokoyama T, Nakamura M. Action of dilazep dihydrochloride on chemiluminescence from a xanthine oxidase/acetaldehyde system. Jpn J Clin Chem. 1990;19: 350-353.
10. 10. Nakamura K, Kojima K, Arai T, et al. Dipyridamole and dilazep suppress oxygen radicals in puromycin aminonucleoside nephrosis rats. Eur J Clin Invest. 1998;28:877-883.
11. 11. Edelstein D, Brownlee M. Mechanistic study of advanced glycosylation end product inhibition by aminoguanidine. Diabetes. 1992;41:26-29.
12. 12. Tanaka Y, Iwamoto H, Onuma T, et al. Inhibitory effect of metformin on formation of advanced glycation end products. Curr Ther Res. 1997;58:693-697.
13. 13. Ferger B, Spratt C, Teismann P, et al. Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Eur J Pharmacol. 1998;360:155-163.
14. 14. McCabe D, Maher TJ, Acworth IN. Improved method for the estimation of hydroxyl free radical levels in vivo based on liquid chromatography with electrochemical detection. J Chromatogr B, Biomed Sci Appl. 1997;691:23-32.
15. e-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry. 1996;35:8075-8083.
16. 16. Tanaka Y, Uchino H, Shimizu T, et al. Effect of metformin on advanced glycation end-product formation and peripheral nerve function in streptozotocin-induced diabetic rats. Eur J Pharmacol. 1999;376:17-22.
17. 17. Morikawa A, Eto M, Makino I. The effect of dilazep on urinary protein excretion in spontaneous diabetic Chinese hamster. Nephron. 1993;65:125-132.
18. 18. Yamamoto M, Fukui M, Kuramoto T, et al. Effects of antiplatelet drug dilazep dihydrochloride on anionic sites and extracellular matrix (ECM) components in glomerular basement membrane of STZ-induced diabetic rats. J Clin Lab Anal. 1995;9:380-386.
19. 19. Tarsio JF, Reger LA, Furcht T. Molecular mechanisms in basement membrane complications of diabetes. Alterations in heparin, laminin, and type IV collagen association. Diabetes. 1988;37:532-539.
20. 20. Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation: Role in the pathogenesis of diabetic complications. Clin Chem. 1988;32:B37-B41.